Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Gets Septin9 Test Reimbursement in France

NEW YORK (GenomeWeb News) – Epigenomics today said that it a French supplementary insurance provider will provide coverage for the firm's Septin9 test for early detection of colorectal cancer.

The Berlin, Germany-based molecular diagnostics firm said that Mutuelle d’Assurance du Corps de Santé Français (MACSF) will reimburse €50 ($68.80) for the test.

MACSF offers additional health insurance to around 800,000 policy holders, according to Epigenomics. It is the second insurer in France to provide reimbursement for Septin9 testing, following a decision last year by Swiss Life to offer the test as part of its preventive health program.

Epigenomics' flagship product is its Epi proColon test, which is based on the Septin9 biomarker. The test is marketed in Europe, and the firm is awaiting a US Food and Drug Administration decision for marketing in the US.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.